Copyright
©The Author(s) 2017.
World J Gastroenterol. May 7, 2017; 23(17): 3133-3141
Published online May 7, 2017. doi: 10.3748/wjg.v23.i17.3133
Published online May 7, 2017. doi: 10.3748/wjg.v23.i17.3133
Table 3 Pathogeny statistics
| Pathogeny | Number | Percent |
| Chronic hepatitis B | 47 | 61.80% |
| Primary biliary cirrhosis | 10 | 13.20% |
| Non-alcoholic fatty liver disease | 5 | 6.60% |
| Chronic drug hepatitis | 4 | 5.30% |
| Autoimmune hepatitis | 2 | 2.60% |
| Alcoholic fatty liver disease | 2 | 2.60% |
| Chronic hepatitis EB | 2 | 2.60% |
| Hemochromatosis | 1 | 1.30% |
| Hyperthyroid liver damage | 1 | 1.30% |
| Hyperbilirubinemia | 1 | 1.30% |
| Portal hypertension | 1 | 1.30% |
- Citation: Li XM, Chen Z, Xiao EH, Shang QL, Ma C. Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis. World J Gastroenterol 2017; 23(17): 3133-3141
- URL: https://www.wjgnet.com/1007-9327/full/v23/i17/3133.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i17.3133